Sugi Predict

Sugi Predict / Compounds / SCHEMBL5896147

SCHEMBL5896147

SCHEMBL5896147

COC(=O)C1(OC)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ EPHX2 P34913 1/20 0.44
▸ EPHX1 P07099 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ PKM P14618 1/20 0.42
▸ GPR119 Q8TDV5 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ TSHR P16473 2/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ RECQL P46063 1/20 0.40
▸ PTPN2 P17706 1/20 0.40
▸ PTPN1 P18031 1/20 0.40
▸ PTPN6 P29350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17631772 0.92 USP2 (0.45) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL12373912 0.92 USP2 (0.45) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL4287443 0.85 USP2 (0.50) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL22118546 0.85 USP2 (0.46) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL5896855 0.85 USP2 (0.50) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL1146902 0.85 USP2 (0.50) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL19216686 0.84 SMN1; SMN2 (0.44) USP2SMN1; SMN2EPHX2HPGDPKM
SCHEMBL27742523 0.84 USP2 (0.44) USP2SMN1; SMN2EPHX2EPHX1PKM
SCHEMBL31566892 0.84 USP2 (0.41) USP2SMN1; SMN2EPHX2EPHX1HPGD
SCHEMBL3498315 0.83 USP2 (0.49) USP2SMN1; SMN2EPHX2EPHX1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727591-A1 SMARCA2 DEGRADERS AND USES THEREOF Astrazeneca AB (SE) 2026-04-22 — — EP disclosed
US-20250289801-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-09-18 — — US disclosed
WO-2025124415-A1 TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS NIKANG THERAPEUTICS INC. (US) 2025-06-19 — — WO disclosed
WO-2025123318-A1 TETRACYCLIC DERIVATIVES AS K-Ras G12D INHIBITORS SHANGHAI BLUERAY BIOPHARMA CO., LTD. (CN) 2025-06-19 — — WO disclosed
CN-115135642-B Inhibitors of EGFR mutant forms 缆图药品公司 2025-03-04 — — CN disclosed
US-12172983-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2024-12-24 — — US disclosed
WO-2024256988-A1 SMARCA2 DEGRADERS AND USES THEREOF ASTRAZENECA AB (SE) 2024-12-19 — — WO disclosed
US-11718602-B2 EGFR inhibitors BLUEPRINT MEDICINES CORPORATION (US) 2023-08-08 — — US disclosed
US-20230056541-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-02-23 — — US disclosed
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2023-02-02 — — US disclosed
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2023-02-02 — — US disclosed
US-20230026209-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-26 — — US disclosed
EP-4081515-A1 INHIBITORS OF MUTANT FORMS OF EGFR Blueprint Medicines Corporation (US) 2022-11-02 — — EP disclosed
CN-115135642-A Inhibitors of mutant forms of EGFR 缆图药品公司 2022-09-30 — — CN disclosed
CN-114007695-A As AM2Heterocyclic spiro-compounds as receptor inhibitors 谢菲尔德大学 2022-02-01 — — CN disclosed
WO-2021133809-A1 INHIBITORS OF MUTANT FORMS OF EGFR BLUEPRINT MEDICINES CORPORATION (US) 2021-07-01 — — WO disclosed
WO-2020099885-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS THE UNIVERSITY OF SHEFFIELD (GB) 2020-05-22 — — WO disclosed
US-7091211-B2 Cyclopentyl modulators of chemokine receptor activity MERCK & CO., INC. (US) 2006-08-15 — — US disclosed
US-20050070609-A1 Cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2005-03-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230056541-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 USP2 2129/4885SMN1; SMN2 4618/4885EPHX2 4141/4885
US-20230026209-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 USP2 2129/4885SMN1; SMN2 4618/4885EPHX2 4141/4885
US-11718602-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 USP2 2129/4885SMN1; SMN2 4618/4885EPHX2 4141/4885
US-12172983-B2 EGFR inhibitors EGFR, ERBB2, ERBB3 USP2 2129/4885SMN1; SMN2 4618/4885EPHX2 4141/4885
US-20230036854-A1 HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS MC2R, AGTR2, NR3C2 USP2 4419/4885SMN1; SMN2 1891/4885EPHX2 400/4885
US-20250289801-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 USP2 2129/4885SMN1; SMN2 4618/4885EPHX2 4141/4885
US-20050070609-A1 Cyclopentyl modulators of chemokine receptor activity CCR5, CXCR1, ACKR3 USP2 4590/4885SMN1; SMN2 4725/4885EPHX2 828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.